This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $100 | 3-6 Days |
| 10mg | $180 | 3-6 Days |
| 25mg | $300 | 3-6 Days |
| 50mg | $500 | 3-6 Days |
| 100mg | $850 | 3-6 Days |
| 250mg | $1350 | 3-6 Days |
| 500mg | $2100 | 3-6 Days |
: Cat #: V3169 CAS #: 1254032-66-0 Purity ≥ 98%
Description: Netarsudil (formerly known as AR-13324; AR13324; trade name Rhopressa) is ROCK inhibitor approved in 2017 for the treatment of glaucoma and ocular hypertension. It inhibits ROCK with Ki of 0.2-10.3 nM. Netarsudil also inhibits norepinephrine transport activity which can reduce the production of aqueous humor. As of 2018, Netarsudil has been approved by FDA for the treatment of glaucoma and ocular hypertension. Previous study showed that at the cellular level, netarsudil was able to induce loss of actin stress fibers, cell shape changes, loss of focal adhesions, as well as changes in extracellular matrix composition of TM cells. Netarsudil primarily targets cells in the conventional outflow tract, efficiently decreasing IOP in both human and non-human primate eyes. In addition, netarsudil has been shown to increase outflow facility in non-human primate eyes and to decrease episcleral venous pressure in rabbit eyes.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 453.54 |
|---|---|
| Molecular Formula | C28H27N3O3 |
| CAS No. | 1254032-66-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: >10mM |
| Water: N/A | |
| Ethanol: N/A | |
| SMILES Code | O=C(OCC1=CC=C([C@@H](CN)C(NC2=CC3=C(C=NC=C3)C=C2)=O)C=C1)C4=CC=C(C)C=C4C |
| Synonyms | AR-13324; AR13324; Rhopressa; AR 13324 |
| Protocol | In Vitro | In vitro activity: Previous study showed that at the cellular level, netarsudil had been shown to be able to induce loss of actin stress fibers, cell shape changes, loss of focal adhesions, as well as changes in extracellular matrix composition of TM cells Kinase Assay: Netarsudil (formerly known as AR-13324) is ROCK inhibitor with Ki of 0.2-10.3 nM. It also inhibits norepinephrine transport activity which can reduce the production of aqueous humor. Cell Assay: Previous study showed that at the cellular level, netarsudil had been shown to be able to induce loss of actin stress fibers, cell shape changes, loss of focal adhesions, as well as changes in extracellular matrix composition of TM cells. |
|---|---|---|
| In Vivo | Animal efficacy study found that the topical treatment of netarsudil was able to affect both proximal (trabecular meshwork and Schlemm's Canal) and distal portions (intrascleral vessels) of the mouse conventional outflow tract. | |
| Animal model | Mice with elevated intraocular pressure (IOP) |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.2049 mL | 11.0244 mL | 22.0488 mL | 44.0975 mL |
| 5mM | 0.4410 mL | 2.2049 mL | 4.4098 mL | 8.8195 mL |
| 10mM | 0.2205 mL | 1.1024 mL | 2.2049 mL | 4.4098 mL |
| 20mM | 0.1102 mL | 0.5512 mL | 1.1024 mL | 2.2049 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.